GL
NTLA icon

GLG LLC’s Intellia Therapeutics NTLA Stock Holding History

GLG LLC’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-34,176
Closed -$730K – 531
2016
Q2 		$730K Buy
+34,176
New +$909K 0.05% 316

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 15.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

GLG LLC's NTLA Position: Q3 2016 in Review

GLG LLC sold out of Intellia Therapeutics (NTLA) in Q3 2016, closing a stake of 34,176 shares — an estimated $730K sold.

GLG LLC first reported a position in NTLA in Q2 2016 and held it in 1 quarter. The position peaked at $730K in Q2 2016. 65 funds tracked by Wall St. Rank hold NTLA as of Q3 2016.

  • GLG LLC reported no remaining Intellia Therapeutics position as of Q3 2016 after selling out during the quarter.
  • GLG LLC sold 34,176 Intellia Therapeutics shares in Q3 2016, an estimated $730K.
  • GLG LLC first reported a position in Intellia Therapeutics in Q2 2016 and held it in 1 quarter.
  • GLG LLC's Intellia Therapeutics position peaked at $730K in Q2 2016.
  • 65 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2016.

Based on GLG LLC's 13F filing for Q3 2016, filed 14 Nov 2016.